Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

Millions are affected by lung conditions, often unaware of risks. Asthma + Lung UK's Andy Whittamore shares tips for ...

Medscape Medical News, May 16, 2019 Alert European Commission OKs Dupilumab for Severe Asthma Dupilumab is for patients with moderate-to-severe asthma and increased blood eosinophil and/or raised ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the results after treating a case of severe asthma with nasal polyps: "After five months of starting Dupilumab frequency of ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Further information NICE will not progress with an appraisal for this indication due to positive guidance in the adult population within TA751. NHS England and Improvement will commission treatments ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.